PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29491081
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20180312
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 3
DP  - 2018 Mar
TI  - Surveillance Imaging in HPV-related Oropharyngeal Cancer.
PG  - 1525-1529
AB  - BACKGROUND/AIM: Current guidelines derived from a pre-human papilloma virus (HPV)
      era in oropharyngeal cancer do not recommend routine surveillance imaging. We
      aimed to analyze the method of recurrence detection in HPV+ disease to determine 
      a role for follow-up imaging. PATIENTS AND METHODS: All HPV+ and HPV-
      oropharyngeal cancer patients treated at our institution from 2005-2016 with
      biopsy-proven recurrence were identified and their method of recurrence detection
      was analyzed. RESULTS: A total of 16 HPV+ oropharyngeal cancer patients were
      identified to have recurrence, 12 (75%) of which experienced distant recurrence
      and 13 (81.3%) were detected asymptomatically with imaging at a median time of
      19.7 months after initial treatment and verifying no residual disease. Twelve
      (75%) detections were with PET-CT. While HPV- patients (17 patients) also have a 
      high rate of asymptomatic detection (16 patients, 94.1%), their 3-year
      post-recurrence survival was significantly lower at 6.5% compared to 83.6% for
      the HPV+ group (p<0.01). CONCLUSION: In HPV+ patients, a large proportion of
      failures are asymptomatic distant metastases, which occur beyond 6 months
      following treatment completion, and are detected with whole body imaging alone.
      In light of long term post-recurrence survival observed, this preliminary data
      suggests that routine surveillance imaging should be further studied for HPV+
      disease.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Su, William
AU  - Su W
AD  - Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.
FAU - Miles, Brett A
AU  - Miles BA
AD  - Department of Otolaryngology Head and Neck Surgery, Icahn School of Medicine at
      Mount Sinai, New York, NY, U.S.A.
FAU - Posner, Marshall
AU  - Posner M
AD  - Department of Medical Oncology, Icahn School of Medicine at Mount Sinai, New
      York, NY, U.S.A.
FAU - Som, Peter
AU  - Som P
AD  - Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY,
      U.S.A.
FAU - Kostakoglu, Lale
AU  - Kostakoglu L
AD  - Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY,
      U.S.A.
FAU - Gupta, Vishal
AU  - Gupta V
AD  - Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New
      York, NY, U.S.A.
FAU - Bakst, Richard L
AU  - Bakst RL
AD  - Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New
      York, NY, U.S.A. [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Oropharyngeal Neoplasms/complications/*diagnostic imaging/*therapy
MH  - Papillomaviridae/physiology
MH  - Papillomavirus Infections/complications/virology
MH  - Positron Emission Tomography Computed Tomography/*methods
MH  - Retrospective Studies
MH  - Salvage Therapy/*methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *CT
OT  - *HPV
OT  - *PET/CT
OT  - *oropharyngeal cancer
OT  - *recurrence detection
OT  - *surveillance imaging
EDAT- 2018/03/02 06:00
MHDA- 2018/03/13 06:00
CRDT- 2018/03/02 06:00
PHST- 2018/01/04 00:00 [received]
PHST- 2018/01/19 00:00 [revised]
PHST- 2018/01/23 00:00 [accepted]
PHST- 2018/03/02 06:00 [entrez]
PHST- 2018/03/02 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
AID - 38/3/1525 [pii]
AID - 10.21873/anticanres.12380 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Mar;38(3):1525-1529. doi: 10.21873/anticanres.12380.